The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
But toxicity will be closely watched in future trials.
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.